Completed PHASE2 INTERVENTIONAL NCT00086203
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
Sponsor: Point Therapeutics
Conditions
Chronic Lymphocytic Leukemia
Interventions
Rituximab Talabostat mesylate (PT-100) tablets
Updated 5 times since 2017 Last updated: Mar 24, 2015 Completion: Sep 30, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2 clinical study on Chronic Lymphocytic Leukemia, this trial is completed. The trial is conducted by Point Therapeutics and has accumulated 5 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Point Therapeutics
Data source: FDA Office of Orphan Products Development
For direct contact, visit the study record on ClinicalTrials.gov .